Please assess the completion status of the following clinical trial:

Trial Title: Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological documentation of small cell lung cancer~* Advanced small cell lung cancer who had at least two chemotherapy regimens,at least one measurable lesion (by RECIST1.1)~* 18-75 years,ECOG PS:0-2,Life expectancy of more than 3 months~* Main organs function is normal~* Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped~* Patients should participate in the study voluntarily and sign informed consent~Exclusion Criteria:~* Patients who have been used anlotinib~* Patients who have been used targeted drugs(such as sunitinib,bevacizumab,endostar),Immune targeted drugs~* 4 weeks or less from the last cytotoxic therapy, radiation therapy or surgery~* Patients whose primary lesion with active bleeding within 4 months~* Carcinomatous meningitis~* Patients who known to the central nervous system~* Patients with factors that could affect oral medication (such as dysphagia，chronic diarrhea, intestinal obstruction etc.)~* Patients with any severe and/or unable to control diseases，including：~  1. Blood pressure unable to be controlled ideally(systolic pressure≥150 mmHg，diastolic pressure≥100 mmHg);~ 2. Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QTc≥450ms(male),QTc≥470ms（female）) and patients with Grade 1 or higher congestive heart failure (NYHA Classification);~ 3. Patients with active or unable to control serious infections;~ 4. Patients with cirrhosis, decompensated liver disease, or active hepatitis;~ 5. Patients with poorly controlled diabetes (fasting blood glucose(FBG)\>10mmol/L)~ 6. Urine protein ≥ ++，and 24-hour urinary protein excretion\>1.0 g confirmed;~* Patients with non-healing wounds or fractures~* Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism~* Patients with drug abuse history and unable to get rid of or Patients with mental disorders~* Imaging showed tumors have involved important blood vessels or by investigators determine likely during the follow-up study and cause fatal hemorrhage~* History of immunodeficiency~* Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Anlotinib (Type: EXPERIMENTAL): Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).